Radiation Oncology

Research & Clinical Trials


Enhancing Care and Improving Outcomes through Research

Penn Radiation Oncology is dedicated to developing new biological and physical approaches that improve radiation therapy and enhance the patient experience.

Penn researchers are widely recognized for developing novel approaches to biologically targeted molecular pathways that enhance the effect of radiation on tumor cells without increasing side effects.

Penn Radiation Oncology's work in tumor hypoxia and the tumor microenvironment is highly regarded in the oncology research community, as are its programs in photodynamic therapy, radioprotection, and DNA damage.

The radiation biology research group - a division of Penn Radiation Oncology - is one of the largest NCI-funded programs in radiation oncology in the country.

The program is an affiliated member of the Radiation Therapy Oncology Group and participates in clinical trials with the Eastern Cooperative Oncology Group and with the Gynecologic Oncology Group.

On the Cutting Edge of Development

As one of only a handful of programs in the nation that offer proton therapy, Penn Radiation Oncology is uniquely positioned to study and expand the applications for this relatively new form of treatment.

To determine the varied uses for proton therapy, Penn Radiation Oncology offers clinical trials for several different treatment sites including head and neck, gynecologic, prostate, brain and lung. It is also exploring the use of proton therapy in the treatment of certain sarcomas and benign conditions.

Penn Radiation Oncology is collaborating with Walter Reed Army Medical Center and Bethesda Naval Hospital on several proton therapy research protocols for active and retired military personnel.

Through a relationship with NASA, Penn Radiation Oncology is working to develop new ways to protect space travelers from radiation.

A complete listing of clinical trials is available on the Abramson Cancer Center website.

Penn Radiation Oncology Researchers